SGLT2 Inhibitor Empagliflozin Is Shown to Be Safe and Effective for Treating Patients Who Have Suffered a Heart Attack

Credit: Mount Sinai Health System

Deepak L. Bhatt, MD, MPH, MBA, Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai led the EMPACT-MI Trial.

« SGLT2 Inhibitor Empagliflozin Is Shown to Be Safe and Effective for Treating Patients Who Have Suffered a Heart Attack

Expert Pitch

Expert Query

Expert Directory